Professor Oliver Ottmann MD, FRCPath

2023

• Mauro, M. J. et al. 2023. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results. Leukemia (10.1038/s41375-023-01860-w)

2022

• Chiriches, C. et al. 2022. Activation of signaling pathways in models of t(6;9)-acute myeloid leukemia. Annals of Hematology 101, pp. 2179-2193. (10.1007/s00277-022-04905-9)
• Chiriches, C. et al. 2022. Understanding a high-risk acute myeloid leukemia by analyzing the interactome of its major driver mutation. PLoS Genetics 18(10), article number: e1010463. (10.1371/journal.pgen.1010463)
• Tazi, Y. et al. 2022. Unified classification and risk-stratification in Acute Myeloid Leukemia. Nature Communications 13(1), article number: 4622. (10.1038/s41467-022-32103-8)
• Konopleva, M. Y. et al. 2022. Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial. Blood Advances 6(14), pp. 4147-4156. (10.1182/bloodadvances.2021006303)
• Sessa, C. et al. 2022. The impact of COVID-19 on cancer care and oncology clinical research: an experts' perspective. ESMO Open 7(1), article number: 100339. (10.1016/j.esmoop.2021.100339)

2021

• Oppliger Leibundgut, E. et al. 2021. Dynamics of mutations in patients with essential thrombocythemia treated with imetelstat. Haematologica 106(9), pp. 2397-2404. (10.3324/haematol.2020.252817)
• Mian, A. A. et al. 2021. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR/ABL1 and its resistance and compound mutants BCR/ABL1T315I and BCR/ABL1T315I-E255K. Annals of Hematology 100, pp. 2023-2029. (10.1007/s00277-020-04357-z)
• Döhner, H. et al. 2021. Adjunctive volasertib in patients with acute myeloid leukemia not eligible for standard induction therapy: a randomized, phase 3 trial. HemaSphere 5(8), article number: e617. (10.1097/FHS9.0000000000000617)
• Martinelli, G. et al. 2021. Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: final analysis of ALCANTARA study. European Journal of Cancer 146, pp. 107-114. (10.1016/j.ejca.2020.12.022)

2020

• Lang, F. et al. 2020. A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia. BMC Pharmacology and Toxicology 21(1), article number: 70. (10.1186/s40360-020-00446-x)
• Rambaldi, A. et al. 2020. Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia. Cancer 126(2), pp. 304-310. (10.1002/cncr.32558)

2019

• Gidman, W., Shah, S., Zhang, L., McKendrick, J., Cong, Z., Cohan, D. and Ottmann, O. 2019. Clinicians' perspectives on cure in adult patients with acute lymphoblastic leukemia with minimal residual disease: A Delphi Study. Advances in Therapy 36(11), pp. 3017-3029. (10.1007/s12325-019-01099-x)
• Mian, A. A. et al. 2019. The phosphatase UBASH3B/Sts-1 is a negative regulator of Bcr-Abl kinase activity and leukemogenesis. Leukemia 33, pp. 2319-2323. (10.1038/s41375-019-0468-y)
• Pfeifer, H. et al. 2019. Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph?+?ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1. Leukemia 33, pp. 1910-1922. (10.1038/s41375-019-0413-0)
• Döhner, H. et al. 2019. A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia. British Journal of Haematology 185(3), pp. 583-587. (10.1111/bjh.15563)
• Ottmann, O. G. et al. 2019. Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia. British Journal of Haematology 184(6), pp. 1018-1021. (10.1111/bjh.15204)
• Cortes, J. E. et al. 2019. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia 33, pp. 379-389. (10.1038/s41375-018-0312-9)

2018

• Ottmann, O. 2018. Tyrosine kinase inhibitor therapy or transplant in children with Philadelphia chromosome-positive acute lymphoblastic leukaemia: striking the balance. Lancet Haematology 5(12), pp. e606-e607. (10.1016/S2352-3026(18)30181-9)
• Brown, J. R. et al. 2018. Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. Lancet Haematology 5(4), pp. e170-e180. (10.1016/S2352-3026(18)30030-9)
• Pfeifer, H. et al. 2018. Genomic CDKN2A/2B deletions in adult Ph+ ALL are adverse despite allogeneic stem cell transplantation. Blood 131(13), pp. 1464-1475. (10.1182/blood-2017-07-796862)
• Legut, M., Dolton, G., Mian, A., Ottmann, O. and Sewell, A. 2018. CRISPR-mediated TCR replacement generates superior anticancer transgenic T-cells. Blood 131(3), pp. 311-322. (10.1182/blood-2017-05-787598)
• Schlenk, R. et al. 2018. Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia, results from two clinical trials. Haematologica 103, pp. e25-e28. (10.3324/haematol.2017.172411)
• Ottmann, O. et al. 2018. Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib. Blood Cancer Journal 8(9), article number: 88. (10.1038/s41408-018-0122-3)

2017

• Garcia-Manero, G. et al. 2017. A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with less than or equal to 30% blasts. Leukemia 31(12), pp. 2799-2806. (10.1038/leu.2017.159)
• Nagel, I. et al. 2017. Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as a potential mechanism of resistance to blinatumomab therapy. Blood 130(18), pp. 2027-2031. (10.1182/blood-2017-05-782888)
• Ottmann, O. 2017. Dasatinib and azacitidine followed by haploidentical stem cell transplant for chronic myeloid leukemia with evolving myelodysplasia: A case report and review of treatment options.. American Journal of Case Reports 18, pp. 1099-1109. (10.12659/AJCR.904956)
• Bug, G. et al. 2017. Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial). Leukemia 31(11), pp. 2523-2525. (10.1038/leu.2017.242)
• Hantschel, O. and Ottmann, O. G. 2017. Allosterische Kinaseinhibitoren. Der Onkologe 23(8), pp. 626-631. (10.1007/s00761-017-0244-4)
• Both, A. et al. 2017. The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemia. Annals of Hematology 96(6), pp. 895-904. (10.1007/s00277-017-2967-0)
• Martinelli, G. et al. 2017. Complete hematologic and molecular response in adult patients with relapsed/refractory philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. Journal of Clinical Oncology 35(16), pp. 1795-1802. (10.1200/JCO.2016.69.3531)
• Gökbuget, N. et al. 2017. Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia. Haematologica 102(4), pp. e132-e135. (10.3324/haematol.2016.153957)
• Lang, F. et al. 2017. Plastic CD34 and CD38 expression in adult B-cell precursor acute lymphoblastic leukemia explains ambiguity of leukemia-initiating stem cell populations. Leukemia 31(3), pp. 731-734. (10.1038/leu.2016.315)
• Oelsner, S. et al. 2017. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma. Cytotherapy 19(2), pp. 235-249. (10.1016/j.jcyt.2016.10.009)

2016

• Oelsner, S. et al. 2016. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival. International Journal of Cancer 139(8), pp. 1799-1809. (10.1002/ijc.30217)
• Giebel, S. et al. 2016. Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a position statement of the Acute Leukemia Working Party of the European Society for blood and marrow transplantation. Cancer 122(19), pp. 2941-2951. (10.1002/cncr.30130)
• Wojcik, B. et al. 2016. Plastic surface marker expression in adult acute lymphoblastic leukemia explains ambiguity of leukemia-initiating stem cell populations. Experimental Hematology 44(9), pp. S108., article number: 3161. (10.1016/j.exphem.2016.06.240)
• Rousselot, P. et al. 2016. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood 128(6), pp. 774-782. (10.1182/blood-2016-02-700153)
• Haense, N. et al. 2016. A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors. BMC Cancer 16(1), pp. 420. (10.1186/s12885-016-2449-0)
• Romanski, A. et al. 2016. CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies. Journal of Cellular and Molecular Medicine 20(7), pp. 1287-1294. (10.1111/jcmm.12810)
• Haberbosch, I., Rafiei, A., Oancea, C., Ottmann, O., Ruthardt, M. and Mian, A. 2016. BCR: a new target in resistance mediated by BCR/ABL-315I?. Genes & Cancer 7(1-2), pp. 36-46.
• Vetter, T. et al. 2016. Blockade of thymic stromal lymphopoietin (TSLP) receptor inhibits TSLP-driven proliferation and signalling in lymphoblasts from a subset of B-precursor ALL patients. Leukemia Research 40, pp. 38-43. (10.1016/j.leukres.2015.10.003)

2015

• Leibundgut, E. O. et al. 2015. Dynamics of mutations in patients with ET treated with Imetelstat. Blood 126(23), article number: 57.
• Bug, G. et al. 2015. Phase I/II Study of the Deacetylase Inhibitor Panobinostat As maintenance therapy after an allogeneic stem cell transplantation in patients with high-risk MDS or AML: The Panobest-Trial. Blood 126(23), article number: 4344.
• Giagounidis, A. et al. 2015. Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from the Phase 2 PACE-MDS Extension Study. Blood 126(23), article number: 92.
• Platzbecker, U. et al. 2015. Biomarkers of ineffective erythropoiesis predict response to Luspatercept in patients with low or intermediate-1 risk Myelodysplastic Syndromes (MDS): final results from the phase 2 PACE-MDS study. Blood 126(23), article number: 2862.
• Martinelli, G. et al. 2015. Complete molecular and hematologic response in adult patients with relapsed/refractory (R/R) Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia (ALL) following treatment with blinatumomab: results from a Phase 2 single-arm, multicenter study (ALCANTARA). Blood 126(23), article number: 679.
• Garcia-Manero, G. et al. 2015. Panobinostat plus azacitidine in adult patients with MDS, CMML, or AML: results of a Phase 2b study. Blood 126(23), article number: 2861.
• Ottmann, O. et al. 2015. ABL001, a potent, allosteric inhibitor of BCR-ABL, exhibits safety and promising single - agent activity in a Phase I study of patients with CML with failure of prior TKI therapy. Blood 126(23), article number: 138.
• Bartels, M. et al. 2015. Deletions of CDKN2A/B and PAX5 are frequently restricted to the CD19+compartment and associated with concurrent deletions of ABL in adult BCR-ABL plus BCP-ALL. Oncology Research and Treatment 38(S5), pp. 90-91., article number: V289. (10.1159/000439070)
• Dengler, J. et al. 2015. Efficacy and safety of nilotinib in routine healthcare: Treatment of CML patients (pts) failing prior therapy - Results of the non-interventional TARGET study. Oncology Research and Treatment 38(S5), pp. 132-133., article number: P452. (10.1159/000439070)
• Pfeifer, H. et al. 2015. European working group for adult ALL phase II trial of nilotinib in combination with chemotherapy for first-line treatment in elderly patients with de novo Philadelphiachromosome positive acute lymphoblastic leukemia (EWALL-PH-02). Oncology Research and Treatment 38(S5), pp. 88., article number: V285. (10.1159/000439070)
• Baerlocher, G. M. et al. 2015. Telomerase inhibitor imetelstat in patients with essential thrombocythemia. New England Journal of Medicine 373, pp. 920-928. (10.1056/NEJMoa1503479)
• Seggewiss-Bernhardt, R. et al. 2015. Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma. Cancer 121(13), pp. 2185-2192. (10.1002/cncr.29339)
• Fiedler, W. et al. 2015. Preliminary phase II results of Ara-C and idarubicin in combination with selective inhibitor of nuclear export (SINE) compound selinexor (KPT-330) in patients with relapsed or refractory AML. Haematologica 100, pp. 221-221.
• Bartels, M. et al. 2015. Clonal Architectures Of Bcr-Abl Plus Bcp-All: Implications For Anti B-Cell Directed Therapy. Haematologica 100(S1), pp. 27., article number: P156.
• Pfeifer, H. et al. 2015. Nilotinib In Combination With Chemotherapy For First-Line Treatment In Elderly Patients With Philadelphia-Positive All: Results Of The European Working Group For Adult All(Ewall-Ph-02). Haematologica 100(S1), pp. 6-7., article number: S113.
• Ottmann, O. et al. 2015. Smoothened (Smo) Inhibitor Lde225 Combined With Nilotinib In Patients With Chronic Myeloid Leukemia (Cml) Resistant/Intolerant (R/I) To At Least 1 Prior Tyrosine Kinase Inhibitor: A Phase 1B Study. Haematologica 100(S1), pp. 62-63., article number: P231.
• DeAngelo, D. J. et al. 2015. Phase III randomized trial of volasertib combined with low-dose cytarabine (LDAC) versus placebo plus LDAC in patients aged >= 65 years with previously untreated, acute myeloid leukemia (AML) ineligible for intensive remission induction therapy. Clinical Lymphoma, Myeloma and Leukemia 15, pp. S194-S194. (10.1016/j.clml.2015.04.046)
• Mian, A. A. et al. 2015. PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation. Leukemia 29(5), pp. 1104-1114. (10.1038/leu.2014.326)
• Rafiei, A. et al. 2015. The functional interplay between the t(9;22)-associated fusion proteins BCR/ABL and ABL/BCR in Philadelphia chromosome-positive Acute Lymphatic Leukemia. PLOS Genetics 11(4), article number: e1005144. (10.1371/journal.pgen.1005144)
• Platzbecker, U. et al. 2015. Luspatercept increases hemoglobin and reduces transfusion burden in patients with low or intermediate-1 risk Myelodysplastic Syndromes (MDS): preliminary results from a phase 2 study. Leukemia Research 39(S1), pp. S25. (10.1016/S0145-2126(15)30054-0)
• Thol, F. et al. 2015. Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemia. Haematologica 100(4), pp. E122-E124. (10.3324/haematol.2014.120345)
• Bug, G. et al. 2015. Panobinostat as maintenance therapy after allogeneic stem cell transplantation in patients with high-risk MDS or AML: Results from the dose-escalation part of the PANOBEST trial. Bone Marrow Transplantation 50, pp. S59-S59. (10.1038/bmt.2015.27)
• Brissot, E. et al. 2015. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. Haematologica 100(3), pp. 392-399. (10.3324/haematol.2014.116954)
• Mian, A. A. et al. 2015. Potential use of allosteric inhibitors as strategy to overcome drug resistance in Ph-positive leukemia. International Journal of Molecular Medicine 36, pp. S26-S26.

2014

• Mian, A., Rafiei, A., Oancea, C., Ottmann, O. and Ruthardt, M. 2014. The functional interplay between the t(9;22)-associated fusion proteins BCR/ABL and ABL/BCR in Philadelphia chromosome positive Acute Lymphatic Leukemia. Blood 124(21), article number: 2402.
• Tesanovic, T., Badura, S., Oellerich, T., Doering, C., Ruthardt, M. and Ottmann, O. 2014. Mechanisms of antileukemic activity of the multikinase inhibitors Dasatinib and Ponatinib in Acute Lymphoblastic Leukemia (ALL) harboring the E2A-PBX1 fusion gene. Blood 124(21), article number: 3595.
• Baerlocher, G. M. et al. 2014. Monitoring of Calr Allele burden in patients with Essential Thrombocythemia treated with Imetelstat, a telomerase inhibitor, reveals rapid and substantial molecular responses. Blood 124(21), article number: 408.
• Zweidler-McKay, P. A. et al. 2014. The safety and activity of BMS-906024, a Gamma Secretase Inhibitor (GSI) with anti-notch activity, in patients with relapsed T-Cell Acute Lymphoblastic Leukemia (T-ALL): initial results of a phase 1 trial. Blood 124(21), article number: 968.
• Wojcik, B. et al. 2014. Functional analysis of the subclonal architecture of B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) at a single cell level. Blood 124(21), article number: 3778.
• Mian, A., Haberbosch, I., Ottmann, O. and Ruthardt, M. 2014. Transphosphorylation of endogenous BCR mediates the effect of T315I on the transformation potential of BCR/ABL. Blood 124(21), article number: 4523.
• Platzbecker, U. et al. 2014. ACE-536 increases hemoglobin and reduces transfusion burden in patients with low or intermediate-1 risk Myelodysplastic Syndromes (MDS): preliminary results from a phase 2 study. Blood 124(21), article number: 411.
• Oancea, C., Heinssmann, M., Guillen, N., Ottmann, O. and Ruthardt, M. 2014. The GSK3 beta-phosphorylation sites in the dek-portion are indispensable for the leukemogenic potential of the dek/can fusion protein in t(6;9)-positive acute myeloid leukemia [Abstract]. Blood 124(21)
• Platzbecker, U. et al. 2014. Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients [Letter]. Leukemia 28(3), pp. 696-698. (10.1038/leu.2013.325)
• Scherr, M. et al. 2014. Differential expression of miR-17 similar to 92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia. Leukemia 28(3), pp. 554-565. (10.1038/leu.2013.361)
• Bug, G. et al. 2014. Long-term results of a prospective randomized trial evaluating G-CSF priming in intensive induction chemotherapy followed by autologous stem cell transplantation in elderly patients with acute myeloid leukemia. Annals of Hematology 93(2), pp. 193-202. (10.1007/s00277-013-1873-3)
• Stegelmann, F. et al. 2014. Follow-up of the non-interventional TARGET study – efficacy and safety of nilotinib in routine clinical management of CML patients (pts) failing prior therapy. Oncology Research and Treatment 37(Supp 1), pp. 84-84.
• Jabbour, E., Ottmann, O., Deininger, M. and Hochhaus, A. 2014. Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies. Haematologica 99(1), pp. 7-18. (10.3324/haematol.2013.087171)
• Ottmann, O. et al. 2014. Nilotinib (Tasigna®) and chemotherapy for first-line treatment in elderly patients with De Novo Philadelphia chromosome/BCR-ABL1 positive acute Lymphoblastic Leukemia (ALL): A trial of the European Working Group for Adult ALL (EWALL-PH-02). Blood 124(21), pp. 798.
• Doehner, H. et al. 2014. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. Blood 124(9), pp. 1426-1433. (10.1182/blood-2014-03-560557)